Clinical Trials Logo

Clinical Trial Summary

This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04102579
Study type Interventional
Source Neurocrine Biosciences
Contact
Status Completed
Phase Phase 3
Start date November 13, 2019
Completion date October 26, 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04400331 - Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease Phase 3
Enrolling by invitation NCT06312189 - Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada Phase 3